Preoperative Radiation Schedules for Breast Cancer

This trial explores two different schedules of radiation therapy for breast cancer patients before surgery. One group receives the standard amount and number of radiation doses (preoperative radiation conventionally fractionated), while the other receives less radiation and fewer doses (preoperative radiation hypofractionated). The trial aims to determine which approach better manages the cancer and prepares for surgery. It may suit those with invasive breast cancer who have not yet undergone mastectomy and are planning tissue-based reconstruction. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that both preoperative radiation schedules for breast cancer are generally safe. For hypofractionated radiation (fewer, larger doses), studies indicate it is well-tolerated. Most patients experience few skin issues, and many have none at all. Over time, the cosmetic results are similar to those of conventional methods.

For conventionally fractionated radiation (more, smaller doses), research also shows a low rate of side effects. Studies find no major difference in complications between the two methods. Some studies even suggest that complications might be slightly lower with conventional radiation.

Researchers are excited about these preoperative radiation schedules for breast cancer because they offer potential improvements over traditional post-surgery radiation. Unlike the standard of care, which typically involves multiple weeks of radiation after surgery, these treatments are administered before surgery, potentially reducing the overall treatment time. Group 1 uses a hypofractionated approach, which delivers higher doses in fewer sessions, possibly leading to quicker completion and less strain on patients. Meanwhile, Group 2 follows a conventionally fractionated schedule but still takes place pre-surgery, which could better target the cancer while it's still intact. These innovative approaches might enhance treatment efficiency and improve patient outcomes.

This trial will compare two preoperative radiation schedules for breast cancer: hypofractionated and conventionally fractionated radiation therapies. Participants in Group 1 will receive hypofractionated radiation, which involves fewer treatment sessions with a higher dose each time. Studies have found this approach effectively controls cancer, with a 98.7% success rate in preventing cancer from returning to the treated area within 3 years, while also shortening treatment time and reducing side effects.